<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602364</url>
  </required_header>
  <id_info>
    <org_study_id>MIGA-FAB</org_study_id>
    <nct_id>NCT04602364</nct_id>
  </id_info>
  <brief_title>French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With Migalastat</brief_title>
  <official_title>A French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With Migalastat - the MIGA-FAB Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amicus Therapeutics France SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amicus Therapeutics France SAS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cohort study to evaluate the effects of migalastat, on long-term safety,&#xD;
      effectiveness, and quality of life (QOL) in patients with Fabry disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Occurrence of key indicators of safety and effectiveness will be evaluated, such as cardiac,&#xD;
      cerebrovascular and renal events, and overall survival. The study is designed to provide&#xD;
      effectiveness and safety data by Q2 2023 which will cover a period up to 5 years after the&#xD;
      migalastat launch date.&#xD;
&#xD;
      This will involve a retrospective data collection up to migalastat initiation (for patients&#xD;
      already receiving migalastat) and a prospective follow-up from 1 to 3.5 years (depending on&#xD;
      the time of enrollment) in migalastat-treated patients with Fabry disease who have a GLA&#xD;
      mutation amenable to migalastat.&#xD;
&#xD;
      All visits will be scheduled and conducted according to the clinical site's standard of care.&#xD;
      Standard of care is defined as a diagnostic and customary clinical treatment/practice process&#xD;
      that a clinician chooses according to their clinical judgement for a Fabry disease patient.&#xD;
      There are no study- required visits, tests or clinical assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - SAEs</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Evaluation of the occurrence ie the number of SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - vital signs</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Evaluation of resting blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness - Fabry Associated Clinical Events (FACEs)</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Evaluation of the occurrence of the FACEs ie total number of cardiac, cerebrovascular, and renal events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness - survival</measure>
    <time_frame>From date of inclusion until the date of death from any cause, assessed up to 60 months</time_frame>
    <description>Survival among all patients enrolled, as assessed by recorded patient death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF-12 12-Item Short Form Health Survey</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Evaluation of QOL by the 12-Item Short Form Health Survey (SF-12) ; the higher the score the worse the quality of life is</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BPI</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Brief pain inventory questionnaire ; the higher the score the more intense the pain is</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FABPRO-GI</measure>
    <time_frame>inclusion to last visit</time_frame>
    <description>Fabry Disease Patient-Reported Outcome-Gastro intestinal Signs and Symptoms Questionnaire ; the higher the score the more importante the GI symptoms are</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac echo imagery</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Echocardiogram (Echo) Left Ventricular Mass Index (LVMI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment compliance</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Patient adherence evaluation (% of taken intakes per month) as reported monthly through self-reports of forgotten intakes by the patient</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Miga-Fab patients</arm_group_label>
    <description>Miga-Fab is a French prospective, observational cohort study of patients with Fabry disease treated with migalastat</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The Miga-Fab is open to participants with Fabry disease treated by migalastat. There is no&#xD;
        predetermined sample size.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Fabry disease aged 16 years or older&#xD;
&#xD;
          -  eGFRCKD-EPI &gt; 30 mL/min/1.73 m2&#xD;
&#xD;
          -  treated with migalastat, or who are starting migalastat upon enrollment&#xD;
&#xD;
          -  Patients with Fabry disease and/or parents/guardians (when applicable) who are able to&#xD;
             understand and have provided a signed non-opposition form.&#xD;
&#xD;
          -  Equipped with a web connection via a computer or tablet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are participating in a clinical trial of any investigational medicinal&#xD;
             product or device at the time of enrollment.&#xD;
&#xD;
          -  Patients already included in the present study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Olivier Lidove, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Diaconnesses Croix Saint Simon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amicus</last_name>
    <phone>0800 906 788</phone>
    <phone_ext>0033</phone_ext>
    <email>info@amicusrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Lavigne, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier Lacombe, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Boulogne sur mer</name>
      <address>
        <city>Boulogne-sur-Mer</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Bataille, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Achille Aouba, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital François Mitterrand</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vanessa Leguy-Seguin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble site Nord, Hôpital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gérard Besson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Hachulla, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Helene Maillard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital femme mère enfant</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain Fouilhoux, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Conception | AP-HM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand Dussol, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agathe Masseau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Lidove, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle Plaisier, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Esther Noel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gregory Pugnet, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Bretagne Atlantique</name>
      <address>
        <city>Vannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Regine Perrichot, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

